Stock NRBO NEUROBO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus NeuroBo Pharmaceuticals, Inc.

Equities

NRBO

US64132R4048

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-07-10 pm EDT 		5-day change 1st Jan Change
4.54 USD +0.22% Intraday chart for NeuroBo Pharmaceuticals, Inc. -2.99% +22.82%
Jun. 26 NeuroBo Pharmaceuticals, Inc. Doses First Patient in the MAD Part 2 of its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity CI
Jun. 26 NeuroBo Pharmaceuticals Raises $20 Million from Share Placement MT

Evolution of the average Target Price on NeuroBo Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

f55.QrPVeiN4sac8UjHmWT-0epIW3ZqkUGfobyp8UwKgtYY.cOPhAlUO8ORFZV2pGlHmT6ohqu_1IiCqXlAjOmbJzNQA0LAVQT75yU4BBQ~ece593000929998dcacc7e8510f7d26e

Analyst Recommendations on NeuroBo Pharmaceuticals, Inc.

Maxim Initiates NeuroBo Pharmaceuticals With Buy Rating, $10 Price Target MT
Ladenburn Thalmann Starts NeuroBo Pharmaceuticals at Buy With $6 Price Target MT
NEUROBO PHARMACEUTICALS : HC Wainwright Adjusts Price Target on NeuroBo Pharmaceuticals to $16 From $20, Reiterates Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.54 USD
Average target price
27.67 USD
Spread / Average Target
+509.40%
High Price Target
48 USD
Spread / Highest target
+957.27%
Low Price Target
10 USD
Spread / Lowest Target
+120.26%

Consensus detail

Consensus revision (last 18 months)

Analysts covering NeuroBo Pharmaceuticals, Inc.

Maxim
Ladenburg Thalmann
HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. NRBO Stock
  4. Consensus NeuroBo Pharmaceuticals, Inc.